RUNX1::RUNX1T1阳性AML的临床特征、预后及可测量残留病监测的临床意义研究中文摘要【目的】1.总结RUNX1::RUNX1TI阳性急性髓系白血病(acutemyeloidleukemia,AML)临床及实验室特征,分析影响其治疗疗效和预后的危险因素。2.分析实时荧光定量聚合酶链反应技术(realtimequantitativepolymerasechainreactionqRT-PCRRUNX1::RUNX1...
Aims: To evaluate the incidence and clinical impact of RUNX1 mutations in a large cohort of younger (16 to 60 years of age) adult AML patients who were entered on AMLSG treatment protocol AML HD98A. Methods: RUNX1 mutation screening was performed in 349 consecutive AML patients (de novo ...
目的探讨基于二代测序检测技术下的克隆性基因突变对第1次完全缓解(CR 1)状态下接受高剂量化疗或自体造血干细胞移植(强化巩固治疗)的RUNX1-RUNX1T1融合基因阳性急性髓系白血病(AML)预后的影响。 方法收集2011年7月至2017年8月在苏州大学附属第一医院CR 1状态下接受强化巩固治疗的79例RUNX1-RUNX1T1融合基因阳性AML...
融合基因是急性髓系白血病(AML)分型的关键标准,对AML预后评估也起到非常关键的作用。AML常见的融合基因有RUNX1::RUNX1T1、CBFB::MYH11、PML::RARA等 [ 1 , 2 ]。其中,伴有RUNX1::RUNX1T1或CBFB::MYH11融合基因的AML,由于都是破坏了核心结合因子(CBF)的转录功能导致的AML,又可称为CBF-AML [ 3 ]。伴...
Protein domains and mutation positions are based on isoform NP_001745.2. RUNT: 85-206, TAD: 318-398, RUNXI: 389-480. (D) Clinical and genetic characteristics of AML patients with germline and somatic RUNX1 mutations. C, complex karyotype; FAB, French-American-British; IQR, interquartile ...
Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia 2002; 16: 1866–1867. CAS PubMed Google Scholar Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia...
RUNX1 mutations, including frameshifts, missense mutations, and gene fusions, are found in a wide variety of tumors such as AML, as well as RUNX1 SNPs in lung adenocarcinoma and colorectal cancer [20,21]. However, RUNX1 has not been shown to carry any pathogenic mutation effects on gliomas...
RUNX1 is a transcription factor and a master regulator for the specification of the hematopoietic lineage during embryogenesis and postnatal megakaryopoiesis. Mutations and rearrangements on RUNX1 are key drivers of hematological malignancies. In humans,
the expected block of differentiation has appeared on CD34 + human cord blood progenitor cells while coming into the differentiation state, with the fusion gene being degraded by CRISPR-Cas9 technology, which may provide novel insights into alternative treatment strategies for M2 AML [20, 23]....
MethodA retrospective study was conducted on the clinical data of seven relapsed/refractory AML patients containing the RUNX1-RUNX1T1 fusion gene and KIT mutation who received afatinib plus allo-HSCT treatment at the First Affiliated Hospital of Soochow University from June 2019 to June 2023. Result...